Pituitary stalk interruption syndrome treatment sales will rise through 2036, driven by hormone replacement at 65.0% of the treatment segment in 2026. The market was valued at USD 121.1 million in 2025 and is expected to be worth USD 173.08 million by 2036, creating an incremental opportunity of USD 47.98 million.